Close Menu

product launch

The company is currently looking for beta customers to test the system for whole-genome sequencing, exome sequencing, and RNA-seq library prep workflows.

The Cambridge, Massachusetts-based firm also said it tacked on $3 million to its Series B financing round for a total of $30 million.

Though 10x will phase out its linked reads technology, it plans to introduce targeted RNA-seq for Chromium and FFPE sample compatibility for Visium.

The company believes cytogeneticists will adopt its panel to get high-quality SNV and CNV data in a single assay.

The company announced the launch of the new products in the US and Europe as part of a product portfolio it has named Panther Scalable Solutions.

The company hopes to help consumer genomics firms and healthcare companies reduce the IT burdens associated with launching a new test.

The firm's whole-genome amplification chemistry may help researchers better understand cancer heterogeneity, even between cells.

Illumina said the NextSeq 2000 and NextSeq 1000 reduce run costs by up to 50 percent, compared to the NextSeq 550 model, while increasing the data output.

Exact Sciences CEO Kevin Conroy discussed the firm's pipeline and plans for 2020 and beyond, while NanoString CEO Brad Gray talked about the company's GeoMx digital spatial profiling technology, among other presentations Wednesday.

On the second day of the conference, updates came not just from the publicly traded industry giants but also privately held firms of interest, such as Caris and GenapSys.

Pages

The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.

The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.

A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.

In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.